Viewing Study NCT05668767


Ignite Creation Date: 2025-12-25 @ 12:53 AM
Ignite Modification Date: 2025-12-25 @ 11:08 PM
Study NCT ID: NCT05668767
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-12-30
First Post: 2022-12-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Sponsor: Beijing Chest Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module